ES2602965T3 - Inhibidores de aril lactama quinasa - Google Patents

Inhibidores de aril lactama quinasa Download PDF

Info

Publication number
ES2602965T3
ES2602965T3 ES13744927.8T ES13744927T ES2602965T3 ES 2602965 T3 ES2602965 T3 ES 2602965T3 ES 13744927 T ES13744927 T ES 13744927T ES 2602965 T3 ES2602965 T3 ES 2602965T3
Authority
ES
Spain
Prior art keywords
mmol
alkyl
retention time
oxy
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13744927.8T
Other languages
English (en)
Spanish (es)
Inventor
Vivekananda M. Vrudhula
Senliang Pan
Ramkumar Rajamani
Susheel Jethanand NARA
Maheswaran Sivasamban KARATHOLUVHU
Tarun Kumar MAISHAL
Jonathan L. Ditta
Carolyn Diane Dzierba
Joanne J. Bronson
John E. Macor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES2602965T3 publication Critical patent/ES2602965T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES13744927.8T 2012-07-31 2013-07-24 Inhibidores de aril lactama quinasa Active ES2602965T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261677856P 2012-07-31 2012-07-31
US201261677856P 2012-07-31
US201313946344 2013-07-19
US13/946,344 US8901305B2 (en) 2012-07-31 2013-07-19 Aryl lactam kinase inhibitors
PCT/US2013/051831 WO2014022167A1 (en) 2012-07-31 2013-07-24 Aryl lactam kinase inhibitors

Publications (1)

Publication Number Publication Date
ES2602965T3 true ES2602965T3 (es) 2017-02-23

Family

ID=50026068

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13744927.8T Active ES2602965T3 (es) 2012-07-31 2013-07-24 Inhibidores de aril lactama quinasa

Country Status (12)

Country Link
US (1) US8901305B2 (enExample)
EP (1) EP2880032B1 (enExample)
JP (1) JP2015528018A (enExample)
CN (1) CN104507941A (enExample)
AR (1) AR093758A1 (enExample)
BR (1) BR112015001890A2 (enExample)
CA (1) CA2880523A1 (enExample)
EA (1) EA201590268A1 (enExample)
ES (1) ES2602965T3 (enExample)
MX (1) MX2015000980A (enExample)
TW (1) TW201410676A (enExample)
WO (1) WO2014022167A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016509066A (ja) 2013-02-22 2016-03-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ アダプター関連キナーゼ１（ａａｋ１）の阻害剤としての５ｈ−クロメノ［３，４−ｃ］ピリジン
WO2015006100A1 (en) 2013-07-08 2015-01-15 Bristol-Myers Squibb Company Aryl amide kinase inhibitors
ES2678877T3 (es) 2013-10-11 2018-08-20 Bristol-Myers Squibb Company Inhibidores de pirrolotriazina quinasa
EP3099300B1 (en) * 2014-01-29 2018-09-05 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
KR102379518B1 (ko) * 2014-04-02 2022-03-25 브리스톨-마이어스 스큅 컴퍼니 비아릴 키나제 억제제
EP3292124B1 (en) * 2015-04-10 2019-05-22 Bristol-Myers Squibb Company 6h-isochromeno[3,4-c]pyridines and benzo[c][1,7]naphthyridin-6-(5h)-ones as adaptor associated kinase 1 (aak1) inhibitors
ES2767776T3 (es) * 2015-10-01 2020-06-18 Bristol Myers Squibb Co Inhibidores de biaril cinasa
US10544120B2 (en) 2015-10-01 2020-01-28 Bristol-Myers Squibb Company Biaryl kinase inhibitors
US20230011378A1 (en) * 2019-08-08 2023-01-12 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Combination Therapy For Treatment Of Cancer
CN114853664B (zh) * 2022-06-02 2023-09-29 河南大学 一种钯催化条件下合成α,β-不饱和杂环己基酮类化合物的方法
CN116102542A (zh) * 2023-02-15 2023-05-12 如东众意化工有限公司 环丙唑醇精制母液中环丙唑醇的回收方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
EP0672031B1 (en) 1992-12-02 2003-03-12 Pfizer Inc. Catechol diethers as selective pde iv inhibitors
US5709861A (en) 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
EP1495009B1 (en) 2002-04-05 2008-03-12 Boehringer Ingelheim Pharmaceuticals Inc. Cyanamides useful as reversible inhibitors of cysteine proteases
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
WO2004072018A1 (ja) 2003-02-12 2004-08-26 Takeda Pharmaceutical Company Limited アミン誘導体
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
RU2006133265A (ru) * 2004-02-18 2008-04-10 Ф.Хоффманн-Ля Рош Аг (Ch) Гетероциклические модуляторы, селективные в отношении подтипа рецептора гамка
WO2006012227A2 (en) 2004-06-24 2006-02-02 Incyte Corporation Amido compounds and their use as pharmaceuticals
CN100494167C (zh) 2005-08-02 2009-06-03 天津大学 抗乙肝病毒的叔胺氧化物及制备方法和制备药物的应用
AU2006326247A1 (en) * 2005-12-15 2007-06-21 F. Hoffmann-La Roche Ag Tricyclic lactam derivatives, their manufacture and use as pharmaceutical agents
JP2007217408A (ja) 2006-01-19 2007-08-30 Tanabe Seiyaku Co Ltd 医薬組成物
EA200801945A1 (ru) * 2006-03-07 2009-02-27 Бристол-Маерс Сквибб Компани Пирролотриазинанилиновые пролекарственные соединения, полезные в качестве ингибиторов киназы
ES2882684T3 (es) 2006-04-07 2021-12-02 Vertex Pharma Preparación de moduladores de transportadores del casete de unión a ATP
US20080039535A1 (en) 2006-08-14 2008-02-14 Wyeth Methods of identifying agents for treating neurological disorders
WO2008079933A2 (en) * 2006-12-22 2008-07-03 Novartis Ag Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
US20100292281A1 (en) * 2009-05-15 2010-11-18 The University Of Kentucky Research Foundation Treatment of mci and alzheimer's disease
FR2955109B1 (fr) * 2010-01-08 2012-09-07 Sanofi Aventis Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique
CN102918045A (zh) * 2010-03-31 2013-02-06 百时美施贵宝公司 作为蛋白激酶抑制剂的取代的吡咯并三嗪
PL2834243T3 (pl) 2012-03-09 2018-09-28 Lexicon Pharmaceuticals, Inc. Związki na bazie pirazolo[1,5-a]pirymidyny, zawierające je kompozycje i sposoby ich zastosowania
WO2013134219A1 (en) 2012-03-09 2013-09-12 Lexicon Pharmaceuticals, Inc. Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
US8703953B2 (en) 2012-03-09 2014-04-22 Bristol-Myers Squibb Company Aryl ether-base kinase inhibitors
HUE036040T2 (hu) 2012-03-09 2018-06-28 Lexicon Pharmaceuticals Inc Adaptor-asszociált kináz 1 gátlása fájdalom kezelésére

Also Published As

Publication number Publication date
CN104507941A (zh) 2015-04-08
CA2880523A1 (en) 2014-02-06
TW201410676A (zh) 2014-03-16
WO2014022167A1 (en) 2014-02-06
MX2015000980A (es) 2015-04-10
BR112015001890A2 (pt) 2017-07-04
US8901305B2 (en) 2014-12-02
EP2880032B1 (en) 2016-10-05
AR093758A1 (es) 2015-06-24
EP2880032A1 (en) 2015-06-10
JP2015528018A (ja) 2015-09-24
EA201590268A1 (ru) 2015-05-29
US20140038999A1 (en) 2014-02-06

Similar Documents

Publication Publication Date Title
ES2602965T3 (es) Inhibidores de aril lactama quinasa
KR102411532B1 (ko) 엔도솜 톨-유사 수용체의 억제제로서의 화합물 및 조성물
ES2885432T3 (es) Derivados de imidazol pentacíclicos condensados
JP6335172B2 (ja) テノホビルプロドラッグおよびその医薬用途
ES2582315T3 (es) Derivado de ftalazinona-cetona, método de preparación de la misma y uso farmacéutico de la misma
US10258626B2 (en) Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them
ES2624263T3 (es) Azaindoles en calidad de agentes antivirales del virus sincitial respiratorio
CA3093527A1 (en) Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
ES2685661T3 (es) Derivado de pirrolopirimidina
JP6487527B2 (ja) スピロ環アリールリン酸化物及びアリールリン硫化物（ｓｐｉｒｏｃｙｃｌｉｃ ａｒｙｌ ｐｈｏｓｐｈｏｒｕｓ ｏｘｉｄｅ ａｎｄ ａｒｙｌ ｐｈｏｓｐｈｏｒｕｓ ｓｕｌｆｉｄｅ）
ES2642762T3 (es) Inhibidores de fosfolipasa A2 asociada a lipoproteínas (LP-PLA2) basados en 2,3-dihidroimidazol[1,2-c]pirimidin-5(1H)-ona
CA2901868C (en) Dihydropyridazine-3,5-dione derivative
CA3115643A1 (en) Amino acid compounds and methods of use
IL297969A (en) Treatment of respiratory diseases with amino acid compounds
CN118434747A (zh) 一种含氮杂环化合物、其制备方法、中间体及应用
RS61693B1 (sr) 4,6-supstituisani-pirazolo[1,5-a]pirazini kao inhibitori janus kinaze
JP7731895B2 (ja) モノアシルグリセロールリパーゼ調節因子
ES2987356T3 (es) Compuestos antiproliferación y usos de los mismos
ES2922029T3 (es) Análogos de hexahidropirimidina antimalaria
CN118382625A (zh) 作为TLR7/8激动剂的吡啶[4,3-d]嘧啶类化合物
TW202237577A (zh) 化合物、組合物及方法
EP4192836A1 (en) Atr inhibitors and uses thereof
ES2881611T3 (es) Producto farmacéutico que contiene inhibidor del transportador de fosfato dependiente de sodio
AU2017247103A1 (en) Synthesis of 2'-fluoro-6'-methylene-carbocyclic adenosine (FMCA) and 2'-fluoro-6'-methylene-carbocyclic guanosine (FMCG)
ES2740224T3 (es) 6H-isocromeno[3,4-c]piridinas y benzo[c][1,7]naftiridin-6-(5H)-onas como inhibidores de la cinasa asociada a adaptador 1 (AAK1)